Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > LATEST
LATEST
-
ARCHIVE R&D NEWS IN BRIEF(2)
July 30, 2007
-
ARCHIVE Revised Therapeutic GL on Breast Cancer Published
July 30, 2007
-
ARCHIVE NEW PRODUCTS
July 30, 2007
-
ARCHIVE Eisai to Launch 3 Major Drugs by FY2011: Mr Naito
July 30, 2007
-
ARCHIVE Prices Should Not Be Cut during Patent Life If Yakkasa Is Smaller than “Dispensing Margins”: EFPIA
July 30, 2007
-
ARCHIVE Long-Listed Drugs Should Be Priced Higher Than Generics: Mr Ohyagi
July 30, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
July 30, 2007
-
ARCHIVE Kyowa Hakko Committed to Successively Developing New Drugs: President Dr Matsuda
July 30, 2007
-
ARCHIVE 3rd Seminar on MR Mammography Fields Hottest Topics on Breast Cancer MRI
July 30, 2007
-
ARCHIVE Pfizer Expanding Supply of Information on JZOLOFT to PCP
July 30, 2007
-
ARCHIVE Pacemakers Are Much Higher-Priced in Japan Than in South Korea, Thailand: Survey
July 30, 2007
-
ARCHIVE Janssen to Differentiate Risperdal from Generics
July 30, 2007
-
ARCHIVE Major Medical Systems Used for 10.3 Years
July 30, 2007
-
ARCHIVE Alfresa to Reduce SGA Expanses Ratio to Below 6% by FY2009
July 30, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
July 30, 2007
-
ARCHIVE 7 Drugs Transiently Excluded from DPC
July 23, 2007
-
ARCHIVE Excessive Thoroughness Should Be Eliminated in Source Data Verification: Seminar
July 23, 2007
-
ARCHIVE Hospital Stay Shortens but Readmission Rate Rises under the Current DPC System
July 23, 2007
-
ARCHIVE Korosho Calls on Pharmacists to Actively Participate in Anticancer Chemotherapy
July 23, 2007
-
ARCHIVE MCH to Search Cerebral Infarction Biomarkers with Kyushu Univ.
July 23, 2007
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…